Answers are grounded in this paper and cite their sources.
Red blood cells (RBCs) are produced across gestation and early life through three sequential waves: primitive, intermediate and definitive, each arising from distinct progenitor populations and occurring at different anatomical sites. Rare inherited anaemias (RIAs) can occur when genetic mutations disrupt the differentiation, maturation or survival of erythroblasts. Because these waves are temporally and spatially segregated, the gestational timing and severity of fetal anaemia can inform both the stage of development where a pathway is required and the stage in which erythropoiesis is disrupted. In this review, we discuss prenatal clinical evaluation and diagnostic pathways for suspected fetal anaemias, including clinical burden and limitations of current management (i.e., transfusion dependence, alloimmunisation and iron overload), in combination with discussion of the genetic and pathway level causes of RIAs. We evaluate the observed defective erythropoiesis (i.e., reduced erythroid output due to impaired progenitor commitment, proliferation or early differentiation) or ineffective erythropoiesis (terminal maturation failure) in RIAs and link these to the common failures observed in vitro stem cell-derived systems. As RIAs can be used to identify pathway checkpoints that when perturbed reduce effective erythroid output in the natural setting, we discuss the importance of disease-informed modelling to inform developmental benchmarks and readouts for laboratory-generated RBCs and support emerging fetal therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Ng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: